已传文件：photo/1773121782.png
The most notable aspect of this article, reported by Fan Kekun, Yan Xizun, and Chen Xuehui from the Institute of Biophysics, Chinese Academy of Sciences, is not merely "another LYTAC was made", but rather that the authors have truly integrated protein nanocages, tumor-targeted delivery, and membrane protein degradation into a modularly expandable platform. Traditional LYTACs are often "one target, one system", which is complex and has poor universality; while this work chose human heavy-chain ferritin HFn as the base, leveraging its own peptide display ability, TfR1-mediated endosomal uptake pathway, and good targeting potential in tumors, to construct an HFn-LYTAC platform that can "replace the target without changing the base".
In more accessible yet professional terms, the core contribution of this article is: advancing ferritin from a "nanocarrier" to a "degradation platform". The authors first conducted structure-guided bioengineering modifications to screen out HFn mutants with higher affinity for TfR1; then, using the SpyTag-SpyCatcher system, they conveniently attached different targeting affibodies to the surface of HFn; finally, they achieved efficient degradation of EGFR, HER2, and PD-L1. That is to say, this is no longer a single case; rather, it proposes a "programmable membrane protein degradation tool" with obvious platform attributes.
The related research was published in Nature Communications under the title "Bioengineered ferritin-based lysosome-targeting chimera platform for tumor targeted therapy".
